JAK/STAT/SOCS-signaling pathway and colon and rectal cancer

Molecular Carcinogenesis

Volumn 52, Issue 2, 2013, Pages 155-166

  Slattery, Martha L ^a   Lundgreen, Abbie ^a   Kadlubar, Susan A ^b   Bondurant, Kristina L ^b   Wolff, Roger K ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cigarette smoking; Colon cancer; Estrogen; JAK; NSAIDs; Rectal cancer; SOCS; STAT

Indexed keywords

ACETYLSALICYLIC ACID; CYTOKINE; ESTROGEN; GAMMA INTERFERON; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE TYK2; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIAGNOSTIC TEST ACCURACY STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATHOPHYSIOLOGY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECTUM CANCER; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; RECTAL NEOPLASMS; SIGNAL TRANSDUCTION; SMOKING; STAT TRANSCRIPTION FACTORS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; STAT4 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SURVIVAL RATE; TYK2 KINASE;

EID: 84872607437     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21841     Document Type: Article

References (34)

1. Lu Y, Zhou J, Xu C, et al. JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 2008; 21: 305-314.
2. Xiong H, Zhang ZG, Tian XQ, et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008; 10: 287-297.
3. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-287.
4. Shea-Donohue T, Fasano A, Smith A, Zhao A. Enteric pathogens and gut function: Role of cytokines and STATs. Gut Microbes 2010; 1: 316-324.
5. Pfitzner E, Kliem S, Baus D, Litterst CM. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des 2004; 10: 2839-2850.
6. Kusaba T, Nakayama T, Yamazumi K, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005; 58: 833-838.
7. Chen B, He L, Savell VH, Jenkins JJ, Parham DM. Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res 2000; 60: 3290-3298.
8. Bromberg JF. Activation of STAT proteins and growth control. Bioessays 2001; 23: 161-169.
9. Yamaoka K, Saharinen P, Pesu M, Holt VE, III, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol 2004; 5: 253.
10. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer-Beyond physical activity. Cancer Res 1997; 57: 75-780.
11. Slattery ML, Edwards S, Curtin K, et al. Physical activity and colorectal cancer. Am J Epidemiol 2003; 158: 214-224.
12. Edwards S, Slattery ML, Mori M, et al. Objective system for interviewer performance evaluation for use in epidemiologic studies. Am J Epidemiol 1994; 140: 1020-1028.
13. Conneely KN, Boehnke M. So many correlated tests, so little time! rapid adjustment of P-values for multiple correlated tests. Am J Hum Genet 2007; 81: 1158-1168.
14. Lees CW, Barrett JC, Parkes M, Satsangi J. New IBD genetics: Common pathways with other diseases. Gut 2011; [epub ahead of print].
15. Hsieh FC, Cheng G, Lin J. Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 2005; 335: 292-299.
16. Slattery ML, Neuhausen SL, Hoffman M, et al. Dietary calcium, vitamin D, VDR genotypes and colorectal cancer. Int J Cancer 2004; 111: 750-756.
17. Caan BJ, Coates AO, Slattery ML, Potter JD, Quesenberry CP, Jr., Edwards SM. Body size and the risk of colon cancer in a large case-control study. Int J Obes Relat Metab Disord 1998; 22: 178-184.
18. Slattery ML, Herrick J, Lundgreen A, Wolff RK. Genetic variation in the TGF{beta}-signaling pathway and colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20: 57-69.
19. Slattery ML, Murtaugh M, Caan B, Ma KN, Neuhausen S, Samowitz W. Energy balance, insulin-related genes and risk of colon and rectal cancer. Int J Cancer 2005; 115: 148-154.
20. Slattery ML, Wolff E, Hoffman MD, Pellatt DF, Milash B, Wolff RK. MicroRNAs and colon and rectal cancer: Differential expression by tumor location and subtype. Genes Chromosomes Cancer 2011; 50: 196-206.
21. Slattery ML, Fitzpatrick FA. Convergence of hormones, inflammation, and energy-related factors: A novel pathway of cancer etiology. Cancer Prev Res (PhilaPa) 2009; 2: 922-930.
22. Ahnen DJ. Colon cancer prevention by NSAIDs: What is the mechanism of action? Eur J Surg Suppl 1998; 582: 111-114.
23. Freedman AN, Slattery ML, Ballard-Barbash R, et al. Colorectal cancer risk prediction tool for white men and women without known susceptibility. J Clin Oncol 2009; 27: 686-693.
24. Kune GA. Colorectal cancer chemoprevention: Aspirin, other NSAID and COX-2 inhibitors. Aust N Z J Surg 2000; 70: 452-455.
25. Sandler RS. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer. Important Adv Oncol 1996; 123-137.
26. Kode A, Yang SR, Rahman I. Differential effects of cigarette smoke on oxidative stress and proinflammatory cytokine release in primary human airway epithelial cells and in a variety of transformed alveolar epithelial cells. Respir Res 2006; 7: 132.
27. Ratovitski EA. DeltaNp63alpha/IRF6 interplay activates NOS2 transcription and induces autophagy upon tobacco exposure. Arch Biochem Biophys 2011; 506: 208-215.
28. Kim M, Miyamoto S, Sugie S, et al. A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice. In Vivo 2008; 22: 557-563.
29. Hussain SP, Harris CC. Inflammation and cancer: An ancient link with novel potentials. Int J Cancer 2007; 121: 2373-2380.
30. Chadwick CC, Chippari S, Matelan E, et al. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc Natl Acad Sci USA 2005; 102: 2543-2548.
31. Cutolo M, Sulli A, Capellino S, et al. Sex hormones influence on the immune system: Basic and clinical aspects in autoimmunity. Lupus 2004; 13: 635-638.
32. Karpuzoglu E, Phillips RA, Dai R, Graniello C, Gogal RM, Jr., Ahmed SA. Signal transducer and activation of transcription (STAT) 4beta, a shorter isoform of interleukin-12-induced STAT4, is preferentially activated by estrogen. Endocrinology 2009; 150: 1310-1320.
33. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 1999; 27: 1583-1592.
34. Starr R, Hilton DJ. SOCS: Suppressors of cytokine signalling. Int J Biochem Cell Biol 1998; 30: 1081-1085.